Monopar reports positive early human data for MNPR-101-Zr tumor targeting

Monopar Therapeutics

MNPR-101-Zr PET image at 168h post-dose in first cancer patient shows high preferential uptake in metastatic tumors.
Uptake aligns with FDG-PET locations; imaging performed on high-sensitivity Siemens Biograph Vision Quadra scanner.
Company aims to launch MNPR-101-Lu Phase 1 therapeutic trial in Q4 2024.
Additional data to be presented at EANM 2024 Congress (Oct 19-23) as 'Top-Rated Oral Presentation'.
MNPR-101 targets uPAR, expressed in majority of triple-negative breast, colorectal, bladder, ovarian, gastric, and pancreatic cancers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.